Y-mAbs Therapeutics Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Y-mAbs Therapeutics does not have a record of paying a dividend.

Wichtige Informationen

n/a

Dividendenausschüttung

-0.4%

Rückkaufsrendite

Gesamte Aktionärsrendite-0.4%
Zukünftige Dividendenrendite0%
Wachstum der Dividenden/a
Nächster Dividendenzahlungsterminn/a
Ex-Dividendendatumn/a
Dividende pro Aktien/a
Ausschüttungsquoten/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers

Oct 21

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33%

Sep 12
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33%

Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)

Aug 12

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Jul 15
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%

Jun 02
Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%

Y-mAbs: There's A Ceiling Here Somewhere

May 09

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Mar 14
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Feb 17
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Y-mAbs Therapeutics: A Monoclonal Antibody Play

Jan 14

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

Nov 13
We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Jul 16
We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

May 13
Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Apr 17
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

Mar 22
Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Dec 13
We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Aug 13
Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Y-mAbs gets FDA nod to begin phase 1 study of GD2-SADA for certain cancers

Jul 12

Y-mAbs Therapeutics: Steady, Small Steps Targeting Rare Cancers

May 30

Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?

May 12
Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Insufficient data to determine if YMAB's dividends per share have been stable in the past.

Wachsende Dividende: Insufficient data to determine if YMAB's dividend payments have been increasing.


Dividendenrendite im Vergleich zum Markt

Y-mAbs Therapeutics Dividendenrendite im Vergleich zum Markt
Wie sieht die Dividendenrendite von YMAB im Vergleich zum Markt aus?
SegmentDividendenrendite
Unternehmen (YMAB)n/a
Untere 25 % des Marktes (US)1.5%
Markt Top 25 % (US)4.5%
Branchendurchschnitt (Biotechs)2.2%
Analystenprognose (YMAB) (bis zu 3 Jahre)0%

Bemerkenswerte Dividende: Unable to evaluate YMAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Hohe Dividende: Unable to evaluate YMAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Insufficient data to calculate YMAB's payout ratio to determine if its dividend payments are covered by earnings.


Barausschüttung an die Aktionäre

Cashflow-Deckung: Unable to calculate sustainability of dividends as YMAB has not reported any payouts.


Entdecken Sie dividendenstarke Unternehmen